Core Insights - Clearmind Medicine Inc. has initiated its Phase I/IIa clinical trial for CMND-100, targeting Alcohol Use Disorder (AUD), marking a significant milestone in the company's development of psychedelic-derived therapeutics [1][3] - The trial aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, with preliminary efficacy assessments to reduce alcohol cravings and consumption [3][4] - The global prevalence of AUD is a major health concern, with approximately 400 million people affected, highlighting the urgent need for innovative treatment solutions [5][6] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [7] - The company's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [8] Clinical Trial Details - The first trial site is located at IMCA in Israel, led by Prof. Mark Weiser, with additional sites at Yale School of Medicine and Johns Hopkins University [2][4] - CMND-100 is a MEAI-based oral drug candidate designed to modulate reward mechanisms associated with addictive behavior, offering a novel approach compared to traditional treatments [4]
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients